***** 15 Live Rounds in AMBS Chamber ***** 2b.

***** 15 Live Rounds in AMBS Chamber *****

2b.) LymPro - incl. patients w/ mild AZ, enrollment 68 patient LP-002 exten. (est. 4Q14)
2c.) LymPro - incl. data announced from full cohort 140 subjects (shortly after 2b above)
03.) LymPro - JV Partnership Agreement (est. 4Q14)
05.) LymPro - Partner validation of APP & CLIA certification (est. 4Q14)

06.) Eltoprazine - 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) Eltoprazine - US IND filed & apvd. for PD-LID (est. 4Q14)

08.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
09.) MANF CVRO / CROA Glaucoma/IND (following animal studies completed 10/07/14)
10.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
11.) MANF RP - Orphan Drug Designation (30 day early FDA apvl. on 11/15)
12.) MANF OIS - Ocular Ischemic Syndrome - ODD applic. filed (est. 4Q14)
13.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
14.) MANF DB-1 Wolframs - orphan potential (est. 4Q14)
15.) MANF - Good Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)
25.) NASDAQ up-listing - (est. 4Q14)


Read more at:

http://investorshangout.com/post/view?id=2160...z3HRlu1g68